[Histonet] RE: IHC antibody optimizing & validating

[joelle weaver]

only 1/2 way through reading the article, but Terri makes a good point about the proficiency testing.  




Joelle Weaver MAOM, HTL (ASCP) QIHC
 
> Date: Wed, 26 Mar 2014 12:48:46 -0400
> From: tbraud <@t> holyredeemer.com
> To: Richard.Cartun <@t> hhchealth.org; histonet <@t> lists.utsouthwestern.edu
> CC: 
> Subject: [Histonet] RE: IHC antibody optimizing & validating 
> 
> Fortunately, they say nothing at all because if that were the case, they
> would no longer be able to peddle their Proficiency Programs for IHC,
> since those too, are fixed and processed elsewhere.  
> 
> Terri L. Braud, HT(ASCP)
> Anatomic Pathology Supervisor
> Holy Redeemer Hospital Laboratory
> 1648 Huntingdon Pike
> Meadowbrook, PA 19046
> Ph: 215-938-3676
> Fax: 215-938-3874
> 
> 
> -----Original Message-----
> From: Cartun, Richard [mailto:Richard.Cartun <@t> hhchealth.org] 
> Sent: Wednesday, March 26, 2014 11:47 AM
> To: Terri Braud; histonet <@t> lists.utsouthwestern.edu
> Subject: RE: IHC antibody optimizing & validating 
> 
> I have not read the entire document yet.  What do they say about using
> tissues that have been fixed and processed elsewhere?
> 
> Richard
> 
> Richard W. Cartun, MS, PhD
> Director, Histology & Immunopathology
> Director, Biospecimen Collection Programs Assistant Director, Anatomic
> Pathology Hartford Hospital
> 80 Seymour Street
> Hartford, CT  06102
> (860) 972-1596 Office
> (860) 545-2204 Fax
> richard.cartun <@t> hhchealth.org
> 
> -----Original Message-----
> From: histonet-bounces <@t> lists.utsouthwestern.edu
> [mailto:histonet-bounces <@t> lists.utsouthwestern.edu] On Behalf Of Terri
> Braud
> Sent: Tuesday, March 25, 2014 3:35 PM
> To: histonet <@t> lists.utsouthwestern.edu
> Subject: [Histonet] RE: IHC antibody optimizing & validating
> 
> CAP is very clear that in order to validate a new antibody, that: "once
> the stain has been optimized, that for a well characterized antibody
> with a limited spectrum of antigenic targets, like Chromogranin or PSA,
> the validation can be limited.  A panel of 10 positive and 10 negative
> neoplasms would be sufficient in this setting.  For an antibody that is
> not well characterized and/or has a wide range of reported reactivity, a
> more extensive validation is necessary.  The number of tissues tested
> should in the circumstance be large enough to determine whether the
> staining profile matches that previously described.  An exception to the
> above requirements is that studies nay not be feasible for antigens such
> as ALK that are only seen in rare tumors."
> Thus sayeth CAP.
> And if you're like me, I am not digging through all my cases to try to
> come up with 30-40 neoplasms for each antibody, so I just order Tissue
> Micro Arrays with the neoplasms I need.  20 positive and 20 negative
> neoplastic tissues on one slide for easy staining and validation.  The
> money you save on reagents to stain one little slide, more than makes up
> for the cost of the slide.
> I hope this helps.
> 
> Terri L. Braud, HT(ASCP)
> ---------------------------------------------------------------------------------
> 
> 
> 
> CONFIDENTIALITY NOTICE:
> 
> This E-Mail is intended only for the use of the individual or entity to which
> it was sent. It may contain information that is privileged and/or confidential,
> and the use or disclosure of such information may also be restricted under applicable
> federal and state law. If you received this communication in error, please do not
> distribute any part of it or retain any copies, and delete the original E-Mail.
> Please notify the sender of any error by E-Mail.
> 
> Thank you for your cooperation.
> 
> 
> _______________________________________________
> Histonet mailing list
> Histonet <@t> lists.utsouthwestern.edu
> http://lists.utsouthwestern.edu/mailman/listinfo/histonet